Odd Lots - D.A. Wallach Explains Why Biotech VC Is So Different

Episode Date: December 12, 2025

Most people think of venture capital as funding software startups or, these days, some new AI tool. But VC also plays a major role in developing new medicines and treatments. That’s the world of D.A. Wallach — though he didn’t start there. Before becoming a biotech investor, Wallach was the lead singer of the indie rock band Chester French. So how did he make the leap from music to venture capital? How does he spot promising biotech opportunities? What does it actually take to bring a new drug to market? And how does biotech investing differ from traditional VC? We talk to the co-founder of Time BioVentures about all of this — plus we get his thoughts on AI’s impact on music and a special performance.Have a question for Joe and Tracy?  Now's your chance to be the perfect guest  - record a voice memo with your name, age, location and question and email to [e-mail] for a chance to be included in the holiday AMA episode.Read More:Big Pharma’s Patent Cliff Puts China Front and CenterNovartis Strikes Deal With UK Biotech for Up To $1.7 BillionJoin the conversation: discord.gg/oddlots Only Bloomberg.com subscribers can get the Odd Lots newsletter in their inbox — now delivered every weekday — plus unlimited access to the site and app. bloomberg.com/subscriptions/oddlotsSee omnystudio.com/listener for privacy information.

The news doesn't stop on the weekends. Context changes constantly. And now Bloomberg is the place to stay on top of it all. Hi, I'm David Gurra. Join us every Saturday and Sunday for the new Bloomberg this weekend. I'm Christina Rafini. We'll bring you the latest headlines, in-depth analysis, and big interviews. All the stories that hit home on your days off.

And I'm Lisa Mateo. Watch and listen to Bloomberg this weekend for thoughtful, enlightening conversations about business, lifestyle, people, and culture. On Saturday mornings, we put the past week's events into context, examining what happened in the markets and the world. That on Sundays we speak with journalists, columnists, and key political figures to prepare you for the week ahead. Join us as soon as you wake up and bring us with you wherever your weekend plans take you. Watch us on Bloomberg Television.

Listen on Bloomberg Radio, stream the show live on the Bloomberg business app, or listen to the podcast. That's Bloomberg this weekend. Saturdays and Sundays starting at 7 a.m. Eastern. Make us part of your weekend routine on Bloomberg Television, radio. and wherever you get your podcasts. Hey there, Oddlots listeners. It is that time of the year.

Again, we are going to be doing a call-in show on the podcast. You can ask us any of your burning questions. That's right. You want to ask us about finance markets and economics? Go for it. You want to ask us about the year in podcasting. Go for it. You want to ask about where Tracy is with growing chicken or raising chickens.

Growing chickens. Raising chickens on her versioning farm in Connecticut. Go for it. This is your chance to ask us anything. Joe's favorite cut of steak, my favorite cut of steak, my favorite Chinese restaurant in the East Village. It's all fair game. All right. All you have to do is send a voice memo with your question, your name, your age, and your location to oddlots at Bloomberg.net. Deadline to submit is December 17th, so get them in as soon as you can. We're looking forward to hearing what you have to ask. And yeah, that's coming up. Bloomberg Audio Studios, Podcasts, Radio News. Hello and welcome to another episode of the Odd Lots podcast.

I'm Tracy Alloway. And I'm Joe Wisenthal. Joe, we were doing a Q&A this morning. That's right. There's a lot of fun. Go on. A live Q&A. And someone asked a question about whether or not we're going to do more health care episodes.

Oh, we don't do enough, do it? No, we don't. And there's a reason for that. I personally am incredibly intimidated by the U.S. healthcare system. I do not understand it at all. It is just a complete mystery to me. But I was very happy to say, in response to that question, that this same day, we're actually recording a healthcare episode with someone that we've wanted to speak to for a long time. I'm the same way in the sense that, first of all, yes. I'm in the same way in the sense that I really do not know much about how the health care system works.

I don't even know where to begin asking the right questions. This is what you do. You have to just start a random episode and that gives you the germs of the next question, the next episode, the next episode. But it seems so big and sprawling, et cetera, that what is the first question to ask? So we just have to plunge right in and just pick one, which we're doing now. And then maybe that will lead to the string of health care episodes, which we should have done a long time ago. That's exactly right. There's also a lot of new stuff happening in health care at the moment, and we've recorded an episode on Chinese biotech a little while ago.

That was incredibly fascinating. Definitely. I'm very curious to see what's going on on the U.S. side of biotech investing. And we do have another episode plan that's sort of tangentially related to that. But clearly there's a lot to talk about. The other very odd-lotsie thing with this guest is we like people who have interesting career histories, right? That's right. How they got to where they are today is often a very interesting question.

You know, I have nothing against people who just took the normal path. People who just sort of, you know, went to college and then they got their MBA. It's okay. You forgive them. I forgive them. That's totally fine. But it's also interesting to hear about the people who maybe walked in through the side door, so to speak. Absolutely. So we do, in fact, have the perfect guest.

We have someone who has a lot of thoughts on U.S. healthcare and who is also a biotech investor. and also formerly the lead singer of Chester French. So, D.A. Wallach, welcome to the show. Thanks so much for coming on. Thanks for having me, guys. I'm a odd lots junkie, so this is like going to the Grammys. Amazing. Did you ever win a Grammy?

No. Don't rub it in. Sorry, sorry, sorry. I shouldn't have. Not yet is the right answer. Not yet. Not yet. Not yet.

I guess my first question should be, can you talk to us about the through line between being a musician and healthcare and biotech and how you got into the space? Because I think, you know, it's not a natural transition to say the least. Yeah, well, I'll tell you how I ended up doing this and then I'll try to connect them theoretically in some way. It might be a little tenuous. I've basically had three careers so far in my limited adult life. I was a professional rock musician with the band that you mentioned for several years. And then I kind of slipped into the venture Capital world when I invested in Spotify about 13 years ago. And that was pretty much the only

company in the private markets I was well positioned to understand as a musician. And through the success of that, I got turned on to how exciting venture capital was, started doing other types of investments across different industries, was involved in SpaceX and Ripple and a bunch of interesting other startups. And then ultimately, a guy I knew started an early stage healthcare company. It was a telemedicine startup called Doctor on Demand. And telemedicine at the time was not a hot topic because this is pre-COVID. So we still primarily went to the doctor in person. And when I made that investment, I started to learn more and more about our healthcare system and was just blown away by how screwed up and stupid it was. And then that eventually evolved into learning more about

biotechnology and the other sub-sectors of healthcare that are critical to medicine. And it's ended up being what I do. In terms of the connection between music and any of this stuff, there are a couple ways I can think about it. One is I tell people, now my job is like being a record producer for scientists. So there's a little bit of a parallel there. But the other is that I think there's a unique challenge in music to combining art and commerce. And in healthcare, there's a similar parallel challenge, which is how do you combine

medicine and capitalism, which don't naturally go together very well? The producer analogy makes a ton of sense. And, you know, there are probably a lot of musicians who are really brilliant, and really great musicians, but for whatever reason, the lightning doesn't strike where they are or doesn't strike nearby and they don't take off. Probably many brilliant scientists, et cetera. but the path from brilliant science to commercial blockbuster can often, I assume, be tricky or dispiriting in many ways, etc. Biotech specifically, of all the things in investing, biotech strikes me as this whole different world than the rest of like investing. You know, when I think of like a software company, it's like, oh, okay, well, they've accumulated these clients and their churn is low, et cetera. Yeah, this seems like a company that has traction is going to grow.

When it comes to biotech, it's like, okay, here's some patent on a sequence and maybe 10 years from now it'll get approved to something that'll be a therapy. It seems so much harder to figure out like what are the heuristics that one would use to establish this is a likely, this science is likely going to turn into a business. Oh, that's absolutely true. It's like a completely different paradigm as an investor. I think the typical biotech company is like a bag of options. and each one of the drugs that the company is working on in success could be worth billions of dollars, but that's 10 years away, often minimum. And so you're trying to price things based on their ultimate potential scale times their

probability of succeeding. And unfortunately, the base rates in terms of probability of success are very low. So if you take small molecules, which is one major area of drugs, the base case is like a 5% probability of success from the original idea to an FDA approval and a marketed drug. Now, you get to a higher sort of prior probability with antibodies or so-called biologics, other classes of drugs that are intrinsically more likely to work than small molecules, but still in every case, you're dealing with very low probabilities of success. And the entire challenge as a biotech investors, how do you manage those low

probability events and build portfolios that are still likely to make money, despite the fact that each individual project is relatively unlikely to work. I'd say in tech, there's this well-described kind of power law distribution of winners and losers, which is to say a very small number of companies make all the money and pay for the huge number of losers. In biotech, that's still true to a degree, but the magnitudes of the winners are lower. And so a really good biotech investor probably has a lower, sorry, a higher batting average than the typical tech investor, but the wins are not as big.

So one thing I'm really curious about is how you source potential investments and how you find, you know, you use the analogy of the record producer, how you find talent in the space or how the talent kind of finds you. and whether or not it's different from, again, the sort of software or tech space that we usually talk about when it comes to venture capital. You know, when I started doing venture investing, it was like I said, 12, 13 years ago, it was obviously a well-established part of the capital markets, but, you know, I cold emailed Brian Armstrong from Coinbase and was meeting with them two days later.

And it's hard to overstate how much. money has rushed in over the past decades. So what went from being an established, but still kind of marginal part of the capital markets is now all anyone thinks or talks about. And so in biotech, what I found getting into this area was that it was more like that venture market I had encountered. There was a scarcity of capital relative to the caliber of ideas that were out there. And so I'd say deal sourcing is much easier in a sense. because there's less money chasing a huge number of good ideas. And those ideas, by and large, do come out of our university and research infrastructure

here in America. The same is also true in other parts of the world, in Europe, China, India, and so forth. But it's really the translation of those academic concepts into products that could make money that is the challenge. That's the so-called valley of death that people sometimes talk about in our industry. There are just an immense number of cool ideas if you go into any university in our country, but such a small number of them is ever going to cross that chasm. And part of that is that the expertise and the personnel required to do that translational work

is not the same expertise that is required to do the inventing in the first place. And so that is really what the large pharmaceutical companies have a specialized expertise in. They train people in this translational work. How do you go from early science to real products? You can get the news whenever you want it with Bloomberg News Now. I'm Amy Morris. And I'm Karen Moscow here to tell you about our new on-demand news report delivered right to your podcast feed. Bloomberg News Now is a short five-minute audio report on the day's time.

stories. Episodes are published throughout the day with the latest information and data to keep you informed. Yes, there are other products like this from a variety of news organizations, but they usually rerun their radio newscasts throughout the day. That's not what we do. We create customized episodes that can only be heard on Bloomberg News Now. And we don't wait an hour to publish breaking news. When news breaks, we'll have an episode up in your podcast feed within minutes. So you're always getting the latest stories and developments. Get the reporting and the context from Bloomberg's 3,000 journalists and analysts we're all over the world. Listen to the latest from Bloomberg News Now on Apple, Spotify, or anywhere you listen.

When I go to like a typical venture capitalist website or I see their Twitter bio or something like that, it'll say like, we back great founders. And I'm like, thanks. That's very helpful because that distinguishes you from the venture capitalists who back crappy founders. I'm glad I'm going to invest with you and said, what's the biotech equivalent? What's the cliche in your industry that every VC says that ostensibly distinguishes them from all the others? Well, I'm not sure what the VCs say. I mean, they are kind of commoditized in the sense that most of the firms look pretty similar. They employ 30 PhDs and physicians. And the value of those people is that they can make sense of the information that you have to process to invest intelligently

in this space. In terms of what distinguishes the founders that they like to look at, I'd say, again, it's kind of the inverse of what you find in tech. There's a real premium on, quote, gray hair in the biotech industry, because the only way to learn this stuff is to do it over and over again and to have had a lot of failures. And if you think about a software company, the tropes you are familiar with are, you know, fail fast, pivot, right? You know, like, you launch something. It doesn't work. You tweak the product design.

You go into a different market. You can adapt very readily to the market. In biotech, if you choose to embark upon a clinical program, you're in for 30 or 40 million bucks. That's not an easy door to walk back out of. And so there's a real premium on people with experience who have done it multiple times. That is a little bit at odds in recent years with a movement that people have, I think, awkwardly dubbed tech bio instead of biotech. And really, these are Silicon Valley tech investors, not totally unlike myself, who have gotten into biotech.

And they think that what's about to change is it's going to go the way of the tech industry. And the next big companies are going to be started by really clever 21-year-olds coming out of Stanford. And that hypothesis, people have been testing now for a few years. I'd say it's a little too early to issue a verdict, but that's never really been our theory. Is that hypothesis just predicated on AI coming in and making, you know, drug development easier? Is that all it is? There's a lot of that. I'd say there are two parts of it. One of it is maybe more substantive than that, and this is a little nuanced, but I know odd lots people like news. nuance, one of the big transformations that really gave rise to the biotech industry.

And when I use that term biotech, I'm distinguishing it from big pharma. So biotech really just means small drug companies. Many of them are public. What really gave rise to that industry was the big pharma at the behest of Wall Street deprioritized early stage research because Wall Street said you're wasting a lot of money on this really risky early stage discovery work, what we would rather you did was just let all these crazy guys like DA finance startups. And once they work, just buy them. You know, you're going to pay a higher price, but you won't be burning all this money on early stuff. What that led to was an

exodus of very specialized technical experts from the pharma companies. And it created the so-called CRO or contract research organization ecosystem. So you now, as a consequence of that for the past 20 years, have had a very proficient environment full of contract organizations that you can hire as a little company to outsource a lot of work that you couldn't in the past. So the best analogy to tech would be sort of like virtual servers or cloud infrastructure. Like, you know, to have a startup, you used to have all these servers in your office, and then at some point you didn't need that. So the cost of new company formation went way down. So part of the argument for younger, more agile founders has been, look, we got this whole new

kind of infrastructure through which they can build companies in a really agile way. The other argument, you know, exactly to your question, is around AI. And that theory is basically, look, these old people don't understand AI. let's get some young Silicon Valley computer sciencey types to do this. And they're going to show them how it's done. I feel like that's probably a phenomenon that goes beyond biotech where there's this fantasy. And maybe in some cases it's even correct. But there is this fantasy that every industry out there must be dominated by old dinosaurs

who don't know how to use tech and who have been doing something the same way forever. And so it's near 2025. it must be out of date by now, and they haven't figured this out. And if we could just... Cough, cough, cough, journalism. Yeah, right. If we could just hire Wiz kids, then we could reinvent the industry from first principles and just do a much better job than the legacy thing.

And I think it's whether it's health care or whether it's industrial stuff that we see Silicon Valley getting excited about right now. It just feels like the default assumption must be that the veterans are doing something wrong. And with pure brain power, we can figure out. what that thing is. I think that is a reasonable characterization of what people say today in a lot of different places. And I don't think it's true in my sector. But as with every conversation about AI, the challenge is balancing two ideas that can be true at the same time but seem contradictory. And one is that this stuff is amazing. And it is particularly in life sciences, responsible

for some true breakthroughs, like the breakthrough that won Demis Sassabas at Deep Mind, the Nobel Prize last year with Alpha Fold, which was this amazing discovery they made that using machine learning models, you could solve a problem that had gone unsolved for decades, which was, can you predict from the sequence of a protein's amino acids what three-dimensional shape a protein is going to take in a physical environment? And I just threw around a bunch of terms of art, but this is fundamental to drug development and drug discovery. So it's like on the one hand, you can't deny these breakthroughs that we're experiencing. You can't deny that when you talk to Gemini, it's staggering what this thing can do.

I mean, I'm sitting there all day having it teach me about asset pricing models or whatever else I'm interested in. But at the same time, the religious movement that is powering all of the investment and a lot of the entrepreneurship here across industries is full of hot air and is making claims that are preposterous unless you are a zealot. Just real quickly, if we had been having this conversation in a month ago, would you have said Gemini or would you have said Chad GPT? Because I switched from Chad GPT to Gemini in the last month and I'm just curious whether you're what you would have said a month. ago. A month ago, I was using all of them. Now I'm only using Gemma. It's interesting. All right. Good data point. Okay. Talk to us about the choke points when it comes to new drug development. Because I imagine, okay, maybe AI machine learning can speed up some of the research or discovery process. But even after that, you have to go through these really long clinical trials that in some cases take decades. What are the major, I guess, like stumbling blocks to getting something to the, the market. Your question held the answer. The process of taking a drug from idea to the market, you can think of as a funnel to just use a visual analogy, and into the top of the funnel go all

the millions of ideas that people have. And then as you go down the funnel, you are spending progressively more and more and more money to prove two things. The first is that the drug is safe and won't harm or kill people. And the second is that the drug works and actually modifies the disease that you're trying to treat. And the tragedy of our moment is that the only way to figure out if drugs are safe and effective is to try them in human beings, living, breathing human beings. And that is extraordinarily time consuming and incredibly expensive financially. So I wish for the day when AI is able to fully simulate an accurate human in the computer, and we don't need to do clinical trials on real people.

But until that moment, the vast majority of the cost and expense and time that is involved in drug discovery remains with us. So most of the AI technologies that people are excited about really would have a lot. the effect of putting more good ideas into the top of the funnel. But unfortunately, that doesn't solve a problem that we have. We already are drowning in good ideas. And the issue is exactly the choke point or bottleneck that you're referring to. This is really, there's actually two questions. First of all, is there low-hanging fruit from a regulatory side to accelerate that process? People like to fathom, oh, the FDA must be super. There's another area. People will say,

well, the FDA must be super slow and do things one way we could speed this up. I don't know. Is there somewhere along the process where, like, from a regulatory standpoint or some other thing that the, either the cost of the timelines could shrink, or is it mostly still just the reality of we have to test these things on humans and that's costly and it takes time? Well, we don't need to do anything. We could have no FDA and anyone who has a good drug idea just launches it commercially. And if some people die from that and it doesn't do anything, that's fine. By the way, that's kind of like the supplement in this. Peptides. And the way we deal with it. Milton Friedman famously thought that the FDA should

only assess the safety of drugs. And if a drug was proven safe, put it on the market and let the market dictate whether people determine they should pay for it based on their lived experience with whether it works or not. Now, I just personally prefer to live in a world where if I've got something that's going wrong, I can more or less trust that the product my doctor gives me has been proven safe and effective. And that reflects that we have today a pretty high bar for approving drugs. But we could certainly lower that bar. We could change the type of data that the FDA requires. And that's what's happening in China, by the way. I know you mentioned this other episode you did with my friend Tim. In China, the regulatory environment has been moving pretty rapidly. And they've

done that deliberately because they want to be more productive. They want to approve more drugs. And they're trying to strike that balance between being prolific and holding things to a high standard at the same time. So, you know, we'll see. And I just want to follow up on one other thing you said, because I think it seems important. Someone like Sam Altman, when he talks about the promise of AI, a lot of it is like, oh, we could find the next drug that cures cancer. In the meantime, we're going to make this sort of slot machine that makes weird videos, et cetera. But really, we're trying to find these wonder drugs in long term. But for what, it sounds like you said, candidates are not where the shortage is. Like, the issue is not that we lack a sufficiently, a number of sufficiently

promising molecule combinations. The scarcity is not on that, at that point. That's my view. I mean, I'll steal me on the other argument. The other argument would be, well, look, D.A., you said 10 minutes ago that these drugs have a 5% probability of working from the outset. You know, if we had better predictive models that told us certain candidates were much more likely to work than others, wouldn't that be great? And my rejoinder to that is, yes, but how would we know that we've done that? Meaning, if the three of us tomorrow invented a black box that produced drug candidate concepts, and we were certain that our model doubled the prior probability,

from 5% to 10%. That would be a truly revolutionary innovation on our part. But how many candidates from that model would we need to take all the way to an approval before we had statistically demonstrated that we, in fact, increased the rate of success? So people may have already cracked that code, you know? Google may have already cracked that code. Sam Altman may have cracked that code. But someone's going to need to spend $30 billion developing the drug ideas he has before we know whether he's done that.

And until that money is spent, it's pure conjecture and salesmanship. This is Tom Keene, inviting you to join us for the Bloomberg Surveillance Podcast. It's about making you smarter every business day. I'm Paul Sweeney. We bring you complete coverage of the U.S. market open. We cover stocks, bonds, commodities, even crypto, all the information you need to excel. And I'm Alexis Christophress. Bloomberg Surveillance also brings you the analysis behind the headlines.

We do that through conversations with the smartest names in economics, finance, investment, and international relations. We do all this live each and every weekday that bring you the best analysis in our daily podcast. Search for Bloomberg Surveillance on Apple, Spotify, YouTube, or anywhere else you listen. On the East Coast, listen at lunch. And on the West Coast, listen as soon as you wake up. That's the Bloomberg Surveillance Podcast with Tom Keene, Paul Sweeney, and me, Alexis Christophores. Subscribe today, wherever you get your podcasts. Bloomberg Surveillance, essential listening each and every business day.

How are you actually evaluating opportunities in the U.S. against China competition? Because, you know, if clinical trials are the major choke point and if China seems to be trying to make that process as efficient as possible, it seems like maybe they have. have an advantage? I mean, they definitely have an advantage. And if I had to make a bet today on our sector, it would be that China is going to be the big story over the next decade or two. I think it's a fundamental structural shift in the global biotechnology market. And their advantages are multiple. I mean, their advantages are regulatory. They relate to the personnel. We have lost an amazing amount of talent who was educated here in our graduate schools and now has gone back to China. And furthermore, they are able to develop things in the clinic, which is to say do clinical

trials, a lot faster and at a much higher volume than our infrastructure can handle. So they've got big advantages. Now, how do I think about investing in the U.S. versus China? I don't that much because I don't speak Mandarin. and I think it would be really difficult for me to invest in China today. But increasingly, companies in the U.S. are starting to outsource certain parts of the research process to Chinese companies, and increasingly they're going to outsource parts of the clinical development process, the clinical trials to China. That's going to make a huge impact on the industry.

Yeah, this was actually my next question. I guess how translatable is a successful clinical trial in China to a market like the U.S.? Three or four years ago, what both investors and regulators in the U.S. would have told you was that it's not that translatable because they're liars and they make up all the data and it's rampant with fraud. And there may have been some truth to that, but I think there was also a good amount of racism. And what sort of woke everyone up in the past couple of years was that some very significant clinical trials were done in China. people were suspicious of the data. Then they replicated those trials in Europe or the United States and got very similar data.

And folks thought, whoa, maybe they're not so bad at this. So I think decreasingly people are skeptical, which said less awkwardly, people are trusting more and more what's coming out of China. And it's incumbent upon the Chinese to the extent that they want this to be a major strategy to continue enhancing people's trust in the quality of their work and their data. If they can do that, I think it's a global industry. A lot of the companies are multinationals. They don't care if the drug comes out of the U.S. or comes out of China.

This is really a question about private or VC stage investing per se, but about biotech more broadly. You know, I've covered the stock market for a long time in various ways. I've never spent any time really getting to know a publicly traded biotech stock. Are you insane to try to invest in biotech if you don't have PhD level understanding of biology? Like, can anyone have alpha in this industry if they don't actually know science? I think it's tough. Yeah.

Seems very tough to me. Look, yeah, I mean, here's the thing. What's really interesting about biotech in the public markets is it's abundantly clear that active investors can have alpha in biotech. Because as you guys know, that is not clear in the rest of the public equity landscape. And so whereas there is very little, if not negative persistence of performance among active equity managers broadly, in biotech, you have a small number of firms that have been doing great for sometimes decades. And it is. And they all have real science expertise on stuff. They do.

And, you know, the dynamic between them and the generalists, so to speak, is that they do a lot of very detailed work to make sense of the information you need to process to value these companies and to assess their probability of success. And then the generalists often follow those specialists into these names. And the fortunes of the industry in these cycles, like we're coming out of a four-year great depression for biotech, I should just mention. A lot of the, those fortunes ride on the sector rotations of the generalists. So the specialists have to stick with biotech because that's what they do. But whether or not companies can IPO, whether or not companies can fund their next clinical trial is largely a function of whether the generalists are in the

sector at that moment or not. And we're just in the midst of the early rotation of generalists back into biotech. Wait, the biotech investing downturn, was that just a function of higher interest rates or was something else going on? It was a confluence of everything that could go wrong at the same time. It was higher interest rates, which really punished these biotech stocks relative to other companies because, you know, no cash flows for 10 years and then a big bolus of money. So these companies are very sensitive to discount rates. Add to that, this dynamic where the generalists had gotten out of the sector. That ultimately is fatal. And then consider

the fact that we had such a come down after the sugar high of COVID. So obviously during COVID, there was this moment of clarity where everyone for a second recognized that this sector is for each of us at some point in our lives the most important thing that happens in the global economy. Like without the biotech industry, you know, we're all in trouble. And we kind of go through life pretending like we're never going to need this industry, and then you get cancer, or your dad gets cancer, or your kid gets some rare disease, and you go, holy cow, I wish I had thought about this before. Maybe all these people who are doing this with their lives are not evil blood suckers who Bernie Sanders needs to take down. And, you know, that is, I think,

part of what dawned on people during COVID when we all were vulnerable and we all were yearning for a solution. Talk a little bit more about, I guess, the financial incentives about actually developing new drugs. So we all know the story of if you're based in the U.S., you can go to Mexico or wherever else and buy the same medicine for like five bucks as opposed to $500 or perhaps even more in the U.S. And the argument for that seems to be that, well, you know, the big pharma companies need to be rewarded for all the research and the effort and the risk that they actually take on. And for some reason, the U.S. seems to be the designated place to do that.

But like, why? Why is my question? Why U.S. drug pricing? Well, the big bounty for a drug development company is the United States market. And that's partly because we as a society have decided that we want. all the new most advanced drugs. We want them first, and we don't want to deny them to people who could benefit from them. Now, the price we pay for those commitments is that our drug prices are higher than the prices in other countries. And the reason their prices are lower is because

their governments choose which drugs their people will have access to. And they make those choices and then negotiate the prices with the companies. And they basically will say to Pfizer or AstraZeneca, look, if you want your drug sold here in Japan, you're going to take the price that we give you. And then the pharma company decides whether they want to accept that deal or not. Now, the United States absolutely could choose as a civilization to negotiate in that same manner. Our government could make the choice for us as to exactly what we're willing to pay for every drug. There would be two consequences to that. One is that we would go without certain drugs.

The second is that a lot of drugs would not even be developed in the first place because the total pool of profits available to drug companies would be much smaller. And so I don't know that there's any perfect answer to how much pharmaceutical innovation we should have in the world. We get to choose how much innovation we want to occur. And the way we choose that is by determining the size of that bounty that exists. How big is the profit pool we want to allow for innovative drug development? And a lot of that is driven by our patent law.

Remember, a patent in this industry is a legalized monopoly. So we give drug companies a legal monopoly for a limited period of time. And that dictates how much money they're able to make off of a new drug. We could shorten the patent life and that would reduce the profit pool. and you'd have less drug development. We could remove the patent life. You could have a permanent monopoly. And believe me, the industry would double or triple overnight.

So it's a choice we have to make, and it's a civic choice. You mentioned the Bernie Sanders of the world who they look at the profits of drug companies, that they look at the prices of drugs. And perhaps if they got their way, there would be less investment in drug discovery, etc. At all, maybe less profits. Going back to COVID, however, there was also the backlash, on the other side, essentially just this deep skepticism towards the premise of pharma and that

what are these scientists doing and why don't they tell you about this root that people have used for thousands of years that cured these diseases that they don't want you to know about so that they can sell you stuff. Talk to us about like just this sort of political environment, investing in biotech in a political environment or a growing number of people, frankly seem to distrust the premise of scientific expertise. Look, it's tough. And some of the blame certainly belongs with the scientific community. Because, you know, to the extent that, say, in the early days of COVID, communication with the public about, say, the value of masks was not clear. And it was maybe even misleading. Some of the presentation

of data regarding the efficacy of the vaccines was not transparent. And that eroded the public's trust in a very understandable way. Now, I'm. no apologist for medicine or science because I don't think these are privileged priesthoods. I think every person should be able to be engaged in and understand science and medicine. And unfortunately, the entire history of medicine began with medical science as total witchcraft and sorcery. So if you go back to antiquity, the first people calling themselves doctors objectively understood nothing. So this was pure sophistry from the beginning.

And we are on this long journey through which medicine is going from total BS and witchcraft to slowly turning into a real science, something that deserves to be called science. medicine is filled with common practices that are not rigorously based on evidence. And that is symptomatic of where we are in that journey that I'm describing. So I'm an advocate for medicine becoming always more and more scientific. I believe that scientific policymakers, scientists in academia need to do a much better job communicating transparently. And that's the only way to engender that kind of trust you're talking about, Joe.

And the trust is critical because it is what gives permission to this industry's existence. Wait, talk more about, I guess, autonomy when it comes to medical decisions. Because this is, you know, a big culture shock of non-Americans who come to the U.S. is drug adverts on TV, where they, you know, here's this great drug, and then they read off all the risk factors really, really quickly. And one of the risks is always death or severe brain damage or something like that. Yeah. And I'm always like, again, I've never asked for a drug that I've seen on TV. I do remember when I first came to the U.S. as an adult, I went to get a prescription.

I found a new doctor to do that. And I said, I needed this thing. And the doctor was like, oh, well, we have to run all these medical tests before we can give you that. and it ended up in a big argument with my insurance provider. And I remember talking to people about that. And they were like, well, you should have pushed back against the doctor about the testing. And I was like, what do I know? I just do what the doctor tells me, right?

How much say should people actually, it sounds weird, but, you know, given the lack of experience and given the way other systems work around the world, how much say should people have in their own medical treatment? I think ultimately they should have almost all of the say. It's your body. Ultimately, you have to make the best decision you can make. And you should regard physicians, nurses, others in the system as consultants who support you in making wise decisions. The one caveat there, however, is that we do socialize a lot of our medical costs. And in many other countries, they completely socialize medical costs. And to the extent that you want the rest of the, of us to pay for your medical care, I do believe we need to have some standards around what it's appropriate to pay for. Yeah, I mean, at the moment, it seems like most of those decisions are left up to the insurers, which, again, in other places in the world, it would be left up to the governments to make those decisions. Are insurers the sort of another limiting factor here?

I believe they are. I believe the private insurance industry adds zero value to the United States health care system, almost. I mean, I may slightly overstate it, but it's close to zero in my book. And I really don't believe insurance companies ought to be the ones making decisions about what medical care is appropriate. I noticed there in the video, you have a really nice looking microphone. Is that a musical, is that a microphone for recording music? Yeah, this is the one I sing on. First of all, you sound good, but it also looks a lot cooler than the typical microphone that are guests. Do you, are you still playing much music? I do, but thankfully now it's just for fun, not for money, which is a much more comfortable place for it to live in my life. Are you, do you think at all about AI generated music and the effect that that's going to have on musicians?

I feel like a lot of musicians, like the ones that I follow on. on Instagram. I say, there's a lot of anxiety about this. There is anxiety. And look, I mean, it's really hard to make a living as a musician. Yeah. Now, it's always been really hard. And, you know, I can't imagine what the lifestyle was of a loot player in George

the Seconds Royal Court or something. But, you know, it's a tough business. And it is scary when new technology comes on the scene that might change the way you make money as an artist. I lived through that with Spotify. People were terrified of it. And, you know, fortunately, what it did over time was dramatically. They should have all done what you did would get long Spotify and then hedge their own risk to it.

But keep going. No, but look, Spotify, by multiples, increased the total revenue of the recorded music business, which was the goal. So mission accomplished. Now, look, AI is going to make music. And I think like all creative people, like journalists, like journalists, like. investors, everyone's going to think about how they can use it to be more effective, have more leverage, have a cooler output. I mean, I have very little doubt that artists are going to do unbelievably cool and original stuff with AI tools, and it's already happening. And for whatever

reason, I have very little trepidation that they're going to be put out of business. Because I think ultimately music is communication. Real quickly on that, when you're talking about, about like doing unbelievably cool things with music. So I see in the background you have a piano, for example. And one of the things when I think about AI music is, and actually I think like, for example, the founder of Suno and some of these other AI music companies have talked about this is like, well, music, learning to play instruments is really hard. And therefore, can we separate in some way the craft of music, the hours that someone has to spend just doing scales on the piano before they can compose something? Maybe you could,

Wouldn't it be nice if we could just have amazing beautiful piano sonatas without ever having put in those thousands of hours? You know, Mary had a little lamb and then so forth. But it does raise the question to my mind of whether one can create great art if they never had to learn the craft. I think the nuance with which one can communicate through music is a function of how many, options you perceive. In other words, if you know the piano inside out, you're aware of so many creative choices that are at your disposal at any given moment. And if your ability to express yourself is squeezed down to what you can put into a natural

language prompt, now those musical ideas are having to pass through the medium of language to be realized. And that inherently erodes the resolution and the expansiveness with which you can express yourself. I feel like there's a danger here that you go off on a big orality tangent and whether ideas can exist without words and things like that. No, but I do think that answer is very insightful. Can you actually create great piano music if you don't know the limits of what the piano can do? And if you're only trying to describe in language, make this beautiful sonata, I think that's very tough, and I thought that answer made a loss.

DA, we're going to have to wrap it up soon. I have one last question, and I'm going to kind of, I'm going to put you on the spot. Can you sing a little odd lot song for us? Like three bars of an odd lot song. I don't care if you generate it with, you know, I guess Gemini now, but you think you could? Let's see. I mean, oh, wow. I'm going to turn this on. Let's see here. This is really cool. If you can. For those who aren't watching the video, so he's moving his microphone, he's moving his microphone to his keyboard. Okay.

Can you see? Yeah, it's great. Yeah, go for it. Come in fruit here. Okay, we're going to try. And it's all about, it's all about, it's all about Tracy. It's all about, it's all about, it's all about Joe. How's that?

That's pretty good. You have a great. voice. Yeah, it is. If you ever want to compose an outro song for us or something like that. Oh, I would love to. I'm, I am the composer of two or three podcasts theme songs. And I have to say, I love your guys theme music. It gets me excited. And I got to end on this for you guys. You know, in high school, the reason I got into investing in high school, I was an economics nerd. Oh, yeah. I heard that you actually wrote like some, a paper that won like a prize from the Fed or something like that?

The Federal Reserve had this nerd competition they sponsored called Fed Challenge. I was the captain of my high school team one year, and we got to D.C. and we saw Greenspan walk out with his wizened face and hands. Anyways, if I had had odd lots to listen to in high school, man, I would have been in heaven because you guys touch on so much interesting stuff. And this just has to be the most exciting thing for young people to experience in order to get turned on to business and economics and finance and recognize these aren't just boring, you know, stayed topics. They're fascinating.

No, thank you for saying that. I really appreciate it. And also, thank you for singing for us. I think that was an all thoughts first. That was the first, yeah. Well, on the spot, I know we've had Morrill Hazard, the country singing economist on before, but that was fantastic. D.A. Wallach, thank you so much for coming on the show. Really appreciate it. Thanks, guys. Thanks for having me. That was great. That was really interesting, Joe. That was super fun. He was great. He was also pretty good at, you know, I know, again, he said it was tenuous, but the through line from music to biotech kind of makes sense. I think it makes a lot of sense. And especially the fact that, you know, these are extreme, these are all startup investing, as we know, you know, there's this power law phenomenon where one of your 20 portfolio company is going to make all the money.

Yeah, the lottery ticket. But, you know, like biotech is like lottery tickets upon lottery tickets. there's so much success uncertainty. Lottery tickets with lower payouts as well. There's so much success uncertainty. There's so much time that elapses between the initial work and where you see if there's any signals of traction. It does feel a lot like the uncertainty that exists in the music industry and selecting which of these hundred bands that all sound great and they're all really talented actually

has what it takes to be a commercial hit. A lot of parallels. Yeah, I thought the dinosaur bias point was an interesting one as well, because you can imagine, like, again, to the timeline point, you kind of have to be old to have any success in the industry historically just because it can take, you know, a decade to get a particular drug to market. So you don't have that much opportunity to have, you know, those wins unless you get old. And there's no shortage. There's no, you know, there may be regulatory things that can be done, but fundamentally, if you want to be. to know whether something works. And if you want to know whether this drug is going to kill people who take it or not, and whether it's safe or not, there is no substitute for doing a test and seeing

what happens. And to your point or to your observation about the dinosaurs, like, I do think that lots of people have this fantasy, that any time there is a legacy industry of any sort, that if you just got 21-year-olds from Stanford in the same room, they would- And gave them a garage to work out of. that they would do it a lot better than the veterans. That was the Doge premise. And Doge doesn't exist anymore. Yeah. Shall we leave it there?

Let's leave it there. This has been another episode of the Odd Lots podcast. I'm Tracy Alloway. You can follow me at Tracy Alloway. And I'm Jill Wisenthal. You can follow me at the stalwart. Follow our guest, D.A. Wollick. He's at D.A. Wollock.

Follow our producers. Carmen Rodriguez at Carmen Armand Dashle Bennett at Dashbot. And Kill Brooks at Kill Brooks. For more OddLod's content, go to Bloomberg. dot com slash odd lots. We have a daily newsletter and all of our episodes. And you can chat about all of these topics 24-7 in our Discord. Discord.g.g. slash oddlots. And if you enjoy oddlots, if you want us to do more healthcare episodes, then please leave us a positive review on your favorite podcast platform. And remember, if you are a Bloomberg subscriber, you can listen to all of our episodes absolutely add free. All you need to do is find the Bloomberg channel on Apple Podcast and follow the instructions there.

Thanks for listening. This is Caroline Hyde. And I'm Ed Ludlow inviting you to join us for Bloomberg Tech, a daily podcast focusing exclusively on technology, innovation and the future of business. Every weekday, we bring you the top headlines from the world's biggest tech companies. From finance to defence, AI to entertainment and from startups to the magnificent seven. We highlight the latest stories of the people and companies pushing the tech sector to new frontiers and the politics that shape global tech markets.

We do this all every weekday. then bring you the most important conversations and analysis in our podcast. Search for Bloomberg Tech on YouTube, Apple, Spotify, or anywhere else you listen. Join us every afternoon on your commute home and stay ahead of the tech news cycle. That's the Bloomberg Tech podcast. I'm Caroline Hyde in New York. And I'm Ed Ludlow in San Francisco. Subscribe today wherever you get your podcasts.